Mineralys Therapeutics Inc’s filing revealed that its 10% Owner Samsara BioCapital GP, LLC acquired Company’s shares for reported $7.5 million on Feb 12 ’24. In the deal valued at $13.50 per share,555,555 shares were bought. As a result of this transaction, Samsara BioCapital GP, LLC now holds 5,074,916 shares worth roughly $69.78 million.
Then, Congleton Jon bought 4,250 shares, generating $25,356 in total proceeds. Upon buying the shares at $5.97, the Chief Executive Officer now owns 1,049,068 shares.
Before that, Congleton Jon bought 2,250 shares. Mineralys Therapeutics Inc shares valued at $27,180 were divested by the Chief Executive Officer at a price of $12.08 per share. As a result of the transaction, Congleton Jon now holds 1,044,818 shares, worth roughly $14.37 million.
Goldman initiated its Mineralys Therapeutics Inc [MLYS] rating to a Buy in a research note published on April 02, 2024; the price target was $30. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early March with a ‘”an Overweight”‘ rating. Stifel began covering MLYS with “Buy” recommendation on March 07, 2023. Guggenheim started covering the stock on March 07, 2023. It rated MLYS as “a Buy”.
Price Performance Review of MLYS
On Monday, Mineralys Therapeutics Inc [NASDAQ:MLYS] saw its stock jump 6.18% to $13.75. Over the last five days, the stock has gained 11.16%. Mineralys Therapeutics Inc shares have risen nearly 59.88% since the year began. Nevertheless, the stocks have fallen -6.14% over the past one year. While a 52-week high of $17.70 was reached on 02/27/24, a 52-week low of $5.85 was recorded on 01/18/24. SMA at 50 days reached $13.04, while 200 days put it at $10.96. A total of 0.52 million shares were traded, compared to the trading of 0.11 million shares in the previous session.
Levels Of Support And Resistance For MLYS Stock
The 24-hour chart illustrates a support level at 13.17, which if violated will result in even more drops to 12.58. On the upside, there is a resistance level at 14.15. A further resistance level may holdings at 14.55. The Relative Strength Index (RSI) on the 14-day chart is 62.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.26, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 6.11%. Stochastics %K at 86.70% indicates the stock is a selling.
The most recent change occurred on March 07, 2023 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating .
